Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Esteve’s Tramadol/Celecoxib: US FDA Cites No Major Concerns, But Also No Advantages
Jan 14 2020
•
By
Sue Sutter
The FDA's review of Esteve's E-58425 reflects the new opioid benefit/risk framework. • Source: Shutterstock
More from US FDA Performance Tracker
More from Regulatory Trackers